Dementia Trials

Can valacyclovir, an antiviral effective against herpes simplex virus, be repurposed to slow cognitive decline in early symptomatic Alzheimer disease among HSV-seropositive patients?

Does oral semaglutide, a GLP-1 receptor agonist with potential anti-inflammatory and neuroprotective effects, slow cognitive and functional decline in early-stage symptomatic Alzheimer's disease (MCI or mild dementia) with biomarker-confirmed amyloid pathology?

Does long-term high-dose gantenerumab treatment remove brain amyloid plaques and delay the onset of clinical symptoms in asymptomatic carriers of dominantly inherited Alzheimer's disease mutations?

Does ALZ-801/valiltramiprosate, an oral amyloid beta oligomer inhibitor, slow cognitive and functional decline in APOE ε4/ε4 homozygotes with early AD (MCI or mild AD) compared to placebo over 78 weeks?

Can combining focused ultrasound blood-brain barrier opening with aducanumab infusion enhance amyloid removal in targeted brain regions compared to aducanumab alone in patients with Alzheimer's disease?

Does low-dose lithium slow cognitive decline and preserve brain volume in adults with mild cognitive impairment?

Can crenezumab, started before symptom onset, prevent or delay cognitive decline in cognitively unimpaired PSEN1 Glu280Ala mutation carriers predestined to develop autosomal-dominant Alzheimer's disease?

Can plasma %p-tau217 clock models estimate the age at biomarker positivity and predict when cognitively unimpaired individuals will develop symptomatic Alzheimer disease?